Urologic Oncology Research Training Grant

泌尿肿瘤学研究培训补助金

• 批准号: 8299404
• 负责人: PETER T SCARDINO
• 金额: $ 27.23万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8299404
• 关键词: Grant; Research Training; Urologic Oncology

DESCRIPTION (provided by applicant): The goal of the T32 research training program in urologic oncology at Memorial Sloan-Kettering Cancer Center (MSKCC) is to train qualified clinician-scientists to be independent investigators in translational research and to progress to full-time academic positions. Dedicated research training in urologic oncology is essential to the mission of the National Cancer Institute (NCI) to eliminate suffering and death from cancer: genitourinary cancers comprise nearly one third of all non-skin cancers and cause 10% of all cancer deaths in the US. T32 fellows gain direct experience in biomedical research by working full-time for 2 years with established basic and translational research scientists. Fellows are also required to participate in structured, multidisciplinary conferences and to present their work at MSKCC seminars and national meetings. T32 preceptors represent the departments of Surgery, Epidemiology and Biostatistics, Medicine, Radiology, and Pathology, as well as 4 of the major research programs at the Sloan-Kettering Institute: Cell Biology, Immunology, Molecular Biology, and Molecular Pharmacology and Chemistry. Areas of research include cancer genetics; signals and pathways involved in the control of cell proliferation; protein targeting; tumor immunology, immunotherapy, and clinical therapeutics, among others. Although fellows may also undertake 1 year of clinical training, they have no clinical responsibilities during their research years unless it is integral to their research project. Most T32 fellows spend 2.5 to 3.5 years completing all research and clinical training. This T32 training grant will continue to support 4 postdoctoral fellows (typically 2 new and 2 continuing trainees) per year. All T32 candidates must have an MD, must have completed training in urology at a residency program approved by the Accreditation Council for Graduate Medical Education (ACGME), and must be board-eligible urologists. T32 fellows usually enter the program during PGY-6 or PGY-7. RELEVANCE: MSKCC's T32 program in urologic oncology trains qualified clinician-scientists for careers focused on eliminating suffering and death from urologic cancers, which comprise 31% of all non-skin cancers and cause 10% of all cancer deaths in the US. To date, 95% of the graduates have matriculated to faculty positions and are engaged in research aimed at understanding and overcoming these cancers.

描述（由申请人提供）：纪念斯隆 - 凯特林癌症中心（MSKCC）的T32泌尿外科肿瘤学研究培训计划的目标是培训合格的临床医生，成为转化研究的独立研究者，并晋升为全日制学位。泌尿外科肿瘤学的专门研究培训对于消除癌症的痛苦和死亡的任务至关重要：泌尿生殖器癌占所有非皮肤癌的近三分之一，在美国所有癌症死亡中的10％。 T32研究员通过与既定基础和转化研究科学家全职工作2年，从而获得了生物医学研究的直接经验。研究员还必须参加结构化的多学科会议，并在MSKCC研讨会和国家会议上介绍他们的工作。 T32受体代表了手术，流行病学和生物统计学，医学，放射学和病理学以及斯隆凯特林研究所的主要研究计划的4个：细胞生物学，免疫学，分子生物学以及分子药理学和化学。研究领域包括癌症遗传学；控制细胞增殖的信号和途径；蛋白质靶向；肿瘤免疫学，免疫疗法和临床疗法等。尽管研究员也可能接受1年的临床培训，但在研究年份中，他们没有临床责任，除非它是其研究项目不可或缺的。大多数T32研究员花费2.5至3。5年来完成所有研究和临床培训。这项T32培训补助金将继续支持每年4名博士后研究员（通常为2名新的和2名持续的学员）。所有T32候选人必须拥有MD，必须在经认证研究生教育认证委员会（ACGME）批准的居住计划中完成泌尿外科培训，并且必须是符合董事会资格的泌尿科医生。 T32研究员通常在PGY-6或PGY-7期间输入该程序。 相关性：MSKCC的T32泌尿外科肿瘤学计划合格的临床医生职业学家，旨在消除泌尿科癌症的痛苦和死亡，泌尿科癌症占所有非皮肤癌的31％，并在美国造成所有癌症死亡的10％。迄今为止，有95％的毕业生已入学到教师职位，并从事旨在理解和克服这些癌症的研究。